title: Long-term viral negativity after interferon for chronic hepatitis C virus infection in hemodialysis.
abstract: OBJECTIVE
  Interferon (IFN) and pegylated-IFN treatment of hepatitis C virus (HCV) infection in hemodialysis patients result in sustained virological response (SVR) rates of 45% and 37%, respectively. Although most nonhemodialysis patients who achieve SVR remain persistently viral negative, the durability of SVR in hemodialysis patients is unknown. We analyzed the rate of long-term virological negativity in hemodialysis patients who achieved SVR after IFN or pegylated-IFN through analysis of patient-level data.
  
  
  METHODS
  After performing a systematic literature review for IFN-based treatment of hemodialysis patients with chronic HCV infection, we extracted patient-level data on patients who achieved SVR. We performed life table analysis to estimate long-term virological negativity rates after SVR in patients who continued on hemodialysis or subsequently underwent kidney transplantation.
  
  
  RESULTS
  Long-term HCV RNA outcomes following SVR were available for 121 hemodialysis patients (20 studies) and 45 patients who subsequently underwent transplantation (11 studies). The probability of remaining HCV RNA negative was 86% (95% confidence interval, 77% to 96%) for patients followed on hemodialysis 48 months after SVR and 95% (95% confidence interval, 89% to 100%) for kidney recipients followed 48 months after transplant.
  
  
  CONCLUSIONS
  Viral negativity from IFN-based HCV treatment in hemodialysis patient appears durable during extended follow-up, including after kidney transplantation. The certainty of the viral negativity estimate is limited by the small number with follow-up beyond 48 months or longer. Transplantation does not confer an increased risk of relapse. Future research should investigate whether IFN-based treatment improves clinical outcomes for hemodialysis patients.
authors.affiliation: Renal Section, Boston University Medical Center, Boston, MA 02118, USA. craig.gordon@bmc.org
authors.forename: Craig E
authors.initials: CE
authors.lastname: Gordon
authors.forename: Katrin
authors.initials: K
authors.lastname: Uhlig
authors.forename: Christopher H
authors.initials: CH
authors.lastname: Schmid
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Levey
authors.forename: John B
authors.initials: JB
authors.lastname: Wong
mesh_terms: D000328:Adult; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008297:Male; D012367:RNA, Viral / Q000032:analysis; D006435:Renal Dialysis
chemical_list: D012367:RNA, Viral; D007372:Interferons